Methylene Blue MMX: Phase II data

An observational Phase II trial in 96 patients undergoing full colonoscopies showed that colonic staining with oral Methylene Blue MMX led to an average polyp detection rate in the whole colon of 1.8 polyps/patient and an adenoma detection rate of 0.9 adenomas/patient. Additionally, the company said polyps were detected in 63.5% of patients, adenomas in 46.9% of patients and serrated lesions in 27.1% of patients. Cosmo said that according to literature, polyps are normally detected in <=35% of patients. The company also said that data published in 2012 from the Cleveland Clinic showed that in 18,003 colonoscopies, the adenoma detection rate was 31.5% and the serrated lesion detection rate was 20.6%. ...